Related Experiment Videos
A new cholescintigraphic agent: ruthenium-97-DISIDA
I Zanzi1, S C Srivastava, G E Meinken
1Division of Nuclear Medicine, North Shore University Hospital, Manhasset, NY 11030.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology
|January 1, 1989
Summary
This study introduces 97Ru-DISIDA as a novel radiotracer for hepatobiliary imaging, showing promising results in human trials. Its convenient half-life and effective diagnostic capabilities suggest it as a viable alternative for specific clinical scenarios.
Area of Science:
- Nuclear Medicine
- Radiopharmaceutical Chemistry
- Diagnostic Imaging
Background:
- Hepatobiliary imaging often requires radiotracers for assessing liver and gallbladder function.
- 131I-rose bengal has been used, but alternatives are sought for specific indications like delayed imaging.
- 97Ru-DISIDA presents a potential new option with favorable pharmacokinetic properties.
Purpose of the Study:
- To evaluate the safety and efficacy of 97Ru-DISIDA in human subjects for the first time.
- To compare the diagnostic performance of 97Ru-DISIDA with existing imaging procedures and clinical findings.
- To assess the dosimetric profile of 97Ru-DISIDA and compare its radiation burden to other commonly used agents.
Main Methods:
- 17 patients (6 weeks to 84 years) underwent cholescintigraphy using radiotracer prepared with a DISIDA labeling kit.
- Cholescintigraphic data was correlated with other imaging modalities and clinical outcomes.
- Dosimetric calculations were performed for 97Ru-DISIDA and compared with 99mTc-DISIDA and 131I-rose bengal.
Main Results:
- The study demonstrated the feasibility of human experiments with 97Ru-DISIDA.
- Cholescintigraphic data obtained with 97Ru-DISIDA showed good correlation with established imaging techniques and clinical assessments.
- Dosimetric data was collected, providing a basis for comparison with other radiotracers.
Conclusions:
- 97Ru-DISIDA is a promising new radiotracer for hepatobiliary imaging, particularly when delayed imaging is necessary.
- Its performance in initial human trials suggests it can serve as a viable alternative to agents like 131I-rose bengal.
- Further studies are warranted to fully establish its clinical utility and optimize its application.